Skip to main content
Fig. 4 | Molecular Cancer

Fig. 4

From: Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer

Fig. 4

Antitumor efficacy of HELA-Exos in an orthotopic TNBC model in vivo. Establishment of a xenograft human tumor model in immunocompetent mice, as described in the methods section, and initiation of therapy. A Schematic diagram of the vaccine dosing regimen in Balb/c mice with orthotopic breast cancer. B and C In vivo tumor imaging in mice was performed using an IVIS Spectrum In Vivo Imaging System at Day 30 after initiation of therapy, and the bioluminescence intensity of the tumor was proportional to the size. The data are presented as the mean ± SD; n = 6. A t test was performed for statistical analysis (***: P < 0.001; **: P < 0.01). D Tumor size was measured every other day after treatment initiation. Tumor growth curves for each mouse are shown. E Immunohistochemical staining examination of Ki67, CASP3, and CRT in tumor tissue. Scale bar, 25 μm. MFI: mean fluorescence intensity

Back to article page